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176Vitamin D deﬁciency is associated with mortality
and adverse vascular access outcomes in patients
with end-stage renal disease
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Background: Plasma 25 hydroxycholecalciferol (vitamin D) deﬁciency has been associated with adverse cardiovascular
outcomes in epidemiologic studies. Chronic kidney disease is associated with loss of 1a-hydroxylase and consequently
vitamin D deﬁciency. We hypothesized that vitamin D deﬁciency was associated with increased mortality and increased
vascular access failure in patients undergoing permanent vascular access for end-stage renal disease.
Methods: This retrospective cohort study analyzed128patients undergoing permanent vascular access surgery between2003
and 2012 for whom concurrent plasma vitaminD levels were also available. Levels were considered deﬁcient at <20 ng/mL.
Multivariable analysis was used to determine the association between vitaminD andmortality and vascular access outcomes.
Results: The mean age was 66.7 years, 96.8% were male, 32.0% were African American, and 60.9% had diabetes mellitus.
In the entire cohort, 55.5% were vitamin D-deﬁcient, despite similar rates of repletion among the vitamin D-deﬁcient and
nondeﬁcient groups. During a median follow-up of 2.73 years, there were 40 deaths (31%). Vitamin D-deﬁcient patients
tended to be younger (P [ .01) and to have higher total cholesterol (P [ .001) and lower albumin (P [ .017) and
calcium (P [ .007) levels. Despite their younger age, mortality was signiﬁcantly higher (P [ .026) and vascular access
failure was increased (P[ .008) in the vitamin D-deﬁcient group. Multivariate logistic regression analysis found vitamin
D deﬁciency (odds ratio [OR], 3.64; 95% conﬁdence interval [CI], 1.12-11.79; P[ .031), hemodialysis through a central
catheter (OR, 3.08; 95% CI, 1.04-9.12; P [ .042), coronary artery disease (OR, 3.08; 95% CI, 1.06-8.94; P [ .039),
increased age (OR, 1.09; 95% CI, 1.03-1.15; P[ .001), and albumin (OR, 0.27; 95% CI, 0.09-0.83; P[ .023) remained
independent predictors of mortality. Vitamin D deﬁciency (hazard ratio [HR], 2.34; 95% CI, 1.17-4.71; P [ .02), a
synthetic graft (HR, 3.50; 95% CI, 1.38-8.89; P [ .009), and hyperlipidemia (HR, 0.42; 95% CI, 0.22-0.81; P [ .01)
were independent predictors of vascular access failure in a Cox proportional hazard model.
Conclusions: Vitamin D deﬁciency is highly prevalent in patients undergoing vascular access procedures. Patients who are
deﬁcient in vitamin D have worse survival and worse vascular access outcomes. Further study is warranted to assess
whether aggressive vitamin D repletion will improve outcomes in this population. (J Vasc Surg 2014;60:176-83.)Chronic kidney disease (CKD) is a worldwide public
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://dx.doi.org/10.1016/j.jvs.2014.01.037been associated with higher all-cause mortality rates, which
increase sharply as kidney function declines. Patients with
stage 3 CKD have a 17% increase in mortality; whereas,
those with stage 5 CKD have a 600% increase in mortality
compared with an age-matched population with normal
renal function.2 Even once HD is initiated, mortality in
the dialysis population remains 10 times greater than
among Medicare patients of a similar age without kidney
disease.3 The expected remaining lifespan is w8 years for
dialysis patients aged 40 to 44 years and w4.5 years for
those aged 60 to 64 years. These values in older patients
are only slightly better than those in patients with lung can-
cer and are much worse than those for the general popula-
tion, which is 30 to 40 years for those aged 40 to 44 years
and 17 to 22 years for individuals aged 60 to 64.3
Performance of a successful HD procedure requires a
functional vascular access that can be cannulated reproduc-
ibly with two needles and deliver adequate dialysis blood
ﬂow.However, vascular access dysfunction is oneof the lead-
ing causes of morbidity in the HD population.4 Medicare
data have estimated that vascular access dysfunction is
responsible for 20% of all hospitalizations in theHD popula-
tion.5,6 The 2007 United States Renal Data System report
found that only 39.4% of prevalent end-stage renal disease
Table I. Patient demographics and clinical data
Variable
Overall Vitamin D level (ng/mL)
P
(N ¼ 128) <20 (n ¼ 71) >20 (n ¼ 57)
Mean/No. SD/% Mean/No. SD/% Mean/No. SD/%
Age, years 66.8 11.7 64.4 12.1 69.7 10.4 .01
Male 124 96.9 68 95.8 56 98.3 .4
African American 41 32.0 24 33.8 17 29.8 .6
Diabetes mellitus 78 60.9 42 59.2 36 63.2 .6
Hypertension 125 97.7 68 95.8 57 100.0 .1
Coronary artery disease 64 50.0 34 47.9 30 52.6 .6
Stroke 19 14.8 15 21.1 4 7.0 .02
Hyperlipidemia 94 73.4 48 67.6 46 80.7 .10
Creatinine, mg/dL 5.0 2.4 5.3 2.5 4.7 2.2 .2
eGFR, mL/min 15.5 6.8 15.7 7.5 15.3 6.2 .8
Albumin, mg/dL 3.4 0.7 3.3 0.5 3.6 0.9 .02
Current smoker 24 18.8 15 21.1 9 15.8 .7
Aspirin 69 53.9 39 54.9 30 52.6 .8
Statin 86 67.2 45 63.4 41 71.9 .3
Total cholesterol, mg/dL 145.3 46.4 158 49.5 128.6 36.3 .001
Triglycerides, mg/dL 137.0 112.8 139.8 116.9 133.1 108.3 .8
Hemoglobin A1c, % 6.3 1.3 6.1 1.1 6.5 1.4 .1
Calcium, mg/dL 8.8 0.7 8.7 0.6 9.0 0.7 .007
Phosphorus, mg/dL 4.5 1.2 4.7 1.4 4.3 1.0 .06
Parathyroid hormone, pg/mL 237.8 175.7 259.1 190.1 210.1 152.1 .1
Hematocrit 34.8 5.2 34.7 4.8 34.9 5.7 .8
Vitamin D replacement 57 44.5 28 39.4 29 50.9 .2
eGFR, Estimated glomerular ﬁltration rate; SD, standard deviation.
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 1 Walker et al 177(ESRD) patients are able to maintain a functioning ﬁstula.7
Autogenous ﬁstulas have a 40% to 70% rate of primary
nonmaturation. This is a major obstacle to increasing ﬁstula
use in theUnited States dialysis population.8 Currently there
are no existing medical therapies aimed at the underlying
pathophysiology of vascular access failure to improve initial
maturation rates of ﬁstulas or prolongﬁstula or graft patency.
Nutritional vitamin D deﬁciency in otherwise healthy
individuals has been associated with higher all-cause mor-
tality. Beyond the well-known mineral metabolism effects,
vitamin D deﬁciency has been associated with hyperten-
sion, insulin resistance, immune abnormalities that enhance
the risk of viral and bacterial infections, autoimmune disor-
ders, cancer, and multiple organ damage due to excessive
systemic inﬂammation that causes atherosclerosis and
vascular dysfunction.9 The frequency and severity of all of
these disorders markedly increase in CKD.10 The multiple
immunomodulatory and anti-inﬂammatory effects of
vitamin D may have particular relevance in the CKD pop-
ulation, given that the uremic state in humans results in a
perturbed biochemical state characterized by inﬂammatory
and oxidative stress as well as vitamin D deﬁciency.11 Given
the known effects of vitamin D in the vasculature,12,13 we
hypothesized that vitamin D deﬁciency in this population
would be associated with increased mortality and poorer
vascular access outcomes.
METHODS
Study design and inclusion criteria. With the ap-
proval of the University of California, San FranciscoInstitutional Review Board, 128 patients from the San
Francisco Veteran’s Administration Medical Center were
identiﬁed who had undergone surgical placement of per-
manent vascular access for HD between 2003 and 2012
and for whom a concurrent vitamin D level was also docu-
mented (plasma 25-hydroxycholecalciferol) as part of
routine clinical care. Patients were excluded if their
vascular access was performed using a bovine graft, if a
vitamin D level was not documented, or if there was no
documented postoperative follow-up. Each patient in the
cohort was unique. For patients who had undergone
placement of multiple ﬁstulas, only the procedure closest
to the date of vitamin D measurement was included in the
data set; all others were excluded. Patients were considered
vitamin D-deﬁcient if their level was #20 ng/mL.14
Plasma 25-hydroxycholecalciferol was used as the metric
of vitamin D status. The immunoassay was run on the
Architect i1000 (Abbott Diagnostics, Lake Forest, Ill),
with a coefﬁcient of variance of <7% and a limit of
detection of 3.1 ng/mL. Given its relative ease of mea-
surement compared with 1,25-dihydroxycholecalciferol
(the active form of vitamin D), 25-hydroxycholecalciferol
is the most widely accepted indicator of vitamin D status
in clinical laboratories.
Electronic medical records were used to compile pa-
tients’ baseline demographics, comorbidities, medications,
and laboratory data. This was performed with the Veterans
Health Information Systems and Technology Architecture
(VistA), an enterprise-wide information system built
around an electronic health record, used throughout the
Fig 1. Distribution of vitaminD levels within the cohort (ng/mL).
Fig 2. Difference in mortality and vascular access failure between
vitamin D-deﬁcient and nondeﬁcient patients.
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system.
Procedure. The type of vascular access placed was at
the discretion of the operating surgeon. However, the pref-
erence at our institution is to only use arteries >2 mm and
veins >3 mm for autogenous access. If these size criteria
are met, we prefer to create radiocephalic ﬁstulas ﬁrst, fol-
lowed by brachiocephalic ﬁstulas at the elbow, then ﬁnally,
a two-stage brachiobasilic ﬁstula. If one of these conditions
is not met, an arteriovenous (AV) graft is placed. Venous
segments are meticulously dissected, ligating all side
branches. Veins are mobilized sufﬁciently to create a
tension-free end-to-side AV anastomosis using a running
6-0 Prolene suture (Ethicon, Somerville, NJ). Vessels are
ﬂushed with heparinized saline before completion of the
anastomosis. Patients do not routinely receive systemic
heparin.
End point deﬁnitions. Clinical end points included
all-cause mortality and vascular access failure. Access-
related events were recorded for each patient, including
interventions designed to maintain or re-establish patency,
access thrombosis, access abandonment, or successful use
of the access for HD.15 Failure was deﬁned as any
thrombosis or abandonment for nonmaturation or patency
reasons. Primary, primary assisted, and secondary patency
were recorded; however, failure, as deﬁned here, equates to
loss of primary assisted patency and is the focus of this
report. Primary and secondary patency rates were not
signiﬁcantly different between the two groups as measured
by the log-rank test. AV ﬁstulas (AVFs) that required
ligation for steal, infection, or transplant were not consid-
ered failures. All of these AVFs were mature, successful
ﬁstulas; however, ligation is a competing event, and these
AVFs were censored as open at the time of ligation. A
mature ﬁstula was clinically deﬁned as one that was able to
sustain adequate blood ﬂows for HD use. Routine sur-
veillance of vascular access is not performed at ourinstitution. Patients are seen#1 month postoperatively and
then as needed thereafter.
Statistical methods. Normally distributed data are rep-
resented with means 6 standard deviations. Non-normally
distributed data are represented as medians with inter-
quartile ranges. Distributions of data were determined using
normal probability plots. Student t-tests and c2 tests were
performed where appropriate to assess for any differences
between the vitamin D-deﬁcient and nondeﬁcient groups.
Univariate and multivariate logistic regression models
were used to assess for independent predictors of survival.
A Cox proportional hazards model and Kaplan-Meier
curve were used to analyze vascular access failure. In each
model, all variables with P value of #.1 in the univariate
analysis were included in the multivariate analysis. Analyses
were performed with and without the 16 grafts; however,
results were not substantially different and conclusions
were unchanged. Therefore, only the analysis of the full
cohort of 128 patients is presented here. All statistical anal-
ysis was performed using STATA 12.1 software (StataCorp
LP, College Station, Tex).
RESULTS
Patient demographics and comorbidities. There
were 339 HD accesses created at our institution between
2003 and 2012. Of these, 119 were excluded due to a
lack of documented vitamin D level, 88 because they
were performed in patients already included in the cohort,
and four because bovine conduit was used. The remaining
cohort included 128 patients with a median follow-up of
2.73 years (interquartile range, 1.00-4.22 years) and a
mean age of 66.8 years (standard deviation, 11.7), 96.9%
were male, and 32.0% were African American. Diabetic
patients comprised 60.9% of the cohort, and 18.8% were
current smokers (Table I). Vitamin D deﬁciency was highly
prevalent, with levels of <20 ng/mL in 71 of the 128
patients (55.5%; Fig 1). Vitamin D levels were measured a
median of 9.5 days from the index procedure, which was
considered time 0.
Patient demographics were similar between the vitamin
D-deﬁcient group and the nondeﬁcient group. This
Table II. Predictors of mortality
Predictor
Univariate Multivariate
P OR 95% CI P
Vitamin D deﬁciency .03 3.64 1.13-11.79 .03
Age .003 1.09 1.03-1.15 .001
AVF vs AVG 1













Albumin .05 0.27 0.09-0.83 .02
Total cholesterol .5
Triglyceride .1





AVF, Arteriovenous ﬁstula; AVG, arteriovenous graft; CI, conﬁdence in-
terval; eGFR, estimated glomerular ﬁltration rate; HD, hemodialysis; OR,
odds ratio; TIA, transient ischemic attack.
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D-deﬁcient group vs 50.9% of the nondeﬁcient group were
taking some form of vitamin D replacement (P ¼ .2).
Notable differences between the groups included that
vitamin D-deﬁcient patients tended to be younger (64.4
vs 69.7 years; P ¼ .01), were more likely to have a pre-
existing history of stroke (21.1% vs 7.0%; P ¼ .02), and
had lower albumin (3.3 vs 3.6 g/dL; P ¼ .02) and calcium
levels (8.7 vs 9.0 mg/dL; P ¼ .007) and higher total
cholesterol (158 vs 129 mg/dL; P ¼ .001; Table I).
Survival. This was a highly morbid cohort, with 40
deaths (31%) during the follow-up. Causes of death were
infection/sepsis in 8, ESRD after stopping HD in 7, car-
diac arrest in 6, cancer in 4, gastrointestinal hemorrhage in
1, and unknown in 14. There were 28 deaths (39%) in the
vitamin D-deﬁcient group vs 12 (21%) in the nondeﬁcient
group (P ¼ .03; Fig 2). Signiﬁcant predictors of death (P <
.1) in our univariate logistic model were vitamin D deﬁ-
ciency, age, initiation of HD through a catheter, coronary
artery disease, albumin, and hemoglobin A1c. These pre-
dictors were entered into a multivariate logistic regression
model (Table II). After adjustment, vitamin D deﬁciency
was the strongest predictor of death, with an odds ratio of
3.64 (95% conﬁdence interval [CI], 1.13-11.79; P ¼ .03).
Receiving HD through a catheter conferred a 3.08 greater
odds of death (95% CI, 1.04-9.11; P ¼ .04), pre-existing
diagnosis of coronary artery disease had 3.07 greater
odds (95% CI, 1.06-8.94; P ¼ .04), and each year increasein age led to a 1.09 increase in odds of death (95% CI,
1.03-1.15; P ¼ .001). Finally, albumin was protective, with
each unit increase translating into a 0.27 odds of death
(95% CI, 0.09-0.83; P ¼ .02).
Fistula types and interventions. Of the procedures
performed, 16 AV grafts were placed and 112 autoge-
nous ﬁstulas: 58 radiocephalic, 32 brachiocephalic, and
22 brachiobasilic. Of these, 65 (50.8%) matured to a us-
able state, and another 80 (63%) underwent additional
interventions to aid maturation and maintain or regain
patency. Procedures performed to maintain patency
were as follows: 41 (32%) patients required balloon an-
gioplasty and ﬁve (4%) required anastomotic revisions.
Another 17 (13%) patients underwent thrombectomy to
regain lost patency. Other ancillary interventions per-
formed unrelated to patency included 23 second-stage
superﬁcializations, 14 venous side-branch ligations, and
3 pseudoaneurysm revisions (Table III). Forty ﬁstulas
(31%) were abandoned due to loss of patency. However,
many of the ﬁstulas underwent ligation for reasons un-
related to patency: 5 for steal syndrome, 10 for transplant
or nonuse, 2 for pseudoaneurysm, and 2 for infection
(Table III).
Failure. We found the incidence of vascular access fail-
ure was signiﬁcantly higher in the vitamin D-deﬁcient
group. This group was much more likely to have interrup-
ted patency (34 events [48%] vs 15 [26%]; P ¼ .008;
Fig 2). In addition, Kaplan-Meier curves showed a signif-
icant difference in the rates of failure between the two
groups (log-rank test ¼ .037; Fig 3). Univariate predictors
of access failure in our Cox proportional hazards model
included vitamin D deﬁciency, initiation of HD through a
catheter, previous failed permanent vascular access, syn-
thetic graft, hypertension, hyperlipidemia, aspirin use,
creatinine level, and hematocrit (Table IV). Vitamin D
deﬁciency, a synthetic graft, and hyperlipidemia remained
statistically signiﬁcant in the multivariate model. After
adjustment, a synthetic graft was the strongest predictor of
failure, with a hazard ratio (HR) of 3.5 (95% CI, 1.38-
8.89; P ¼ .009). However, vitamin D deﬁciency remained
a strong predictor, with a HR of 2.34 (95% CI, 1.17-4.71;
P ¼ .02). Finally, a history of hyperlipidemia was protec-
tive, with a HR of 0.42 (95% CI, 0.22-0.81; P ¼ .01).
Location of ﬁstula creation (wrist, elbow) was not predic-
tive of failure.
DISCUSSION
The purpose of this study was to investigate the hy-
pothesis that the potentially modiﬁable risk factor of
vitamin D deﬁciency is associated with death and access
failure. We found that vitamin D deﬁciency was highly
prevalent in this cohort, with levels in 55.5% of the patients
of <20 ng/mL, the commonly used cutoff for severe deﬁ-
ciency.14 This was despite similar rates of vitamin D
replacement therapy. The ESRD population is at high
risk for vitamin D deﬁciency. The reasons for this are multi-
factorial but are at least partly due to the progressive
decline in production of 1a-hydroxylase from the kidney.16
Table III. Procedure characteristics
Variable
Overall (N ¼ 128)
Vitamin D level (ng/mL)
P
<20 (n ¼ 71) >20 (n ¼ 57)
No. % No. % No. %
Fistula type
Cimino 58 45.3 37 52.1 21 36.8 .05
Brachiocephalic 32 25.0 17 23.9 15 26.3 .4
Brachiobasilic 22 17.2 8 11.3 14 24.6 .04
AV graft 16 12.5 9 12.7 7 12.3 .6
Interventions
Balloon angioplasty 41 32.0 21 29.6 20 35.1 .6
Thrombectomy 17 13.3 14 19.7 3 5.3 .02
Branch ligation 14 10.9 9 12.7 5 8.8 .6
Pseudoaneurysm revision 3 2.3 3 4.2 0 d .3
Anastomotic revision 5 3.9 2 2.8 3 5.3 .7
2nd-stage superﬁcialization 23 18.0 10 14.1 13 22.8 .2
Outcomes
Mature 65 50.8 36 50.1 29 50.9 .4
Thrombosed 42 32.8 27 38 15 26.3 .1
Ligated
Steal 5 3.9 2 2.8 3 5.3 .7
Transplant/nonuse 10 7.8 8 11.3 2 3.5 .2
Pseudoaneurysm 2 1.6 1 1.4 1 1.8 1.0
Infection 2 1.6 2 2.8 0 . .5
AV, Arteriovenous.
Fig 3. Kaplan-Meier curve shows access failure by vitamin D-deﬁcient and nondeﬁcient status.
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late the active form of the hormone, 1,25-dihydroxy
vitamin D.
Beyond its traditionally known mineral metabolism ef-
fects, vitamin D is now recognized to have multiple effects
in a wide range of tissue types, including the vasculature.
Vitamin D deﬁciency is associated with increased arterial
stiffness, as assessed by pulse wave velocity, and with
decreased endothelial function, as assessed by ﬂow-mediated vasodilation in patients with ESRD.17 Partial
reversibility of vascular changes is evidenced by the fact
that vitamin D replacement reduces left ventricular mass in-
dex by 9% to 10% in vitamin D-deﬁcient patients,12 reduces
pulse wave velocity,18 and improves the elastic properties
of arteries.19 The vascular effects of vitamin D may be
mediated through vitamin D receptors and peripheral 1a-
hydroxylase, both present in endothelial and smooth mus-
cle cells of the vascular wall.20




P HR 95% CI P




HD by central catheter .08 1.50 0.74-3.06 .3
Previous failed AVF/AVG .0002 1.50 0.56-3.85 .4




Hypertension .002 .20 0.04-1.01 .051
Hyperlipidemia .02 .42 0.22-0.81 .01
Diabetes mellitus .2
Tobacco use .4
Aspirin .09 .67 0.37-1.23 .2
Statin .2
eGFR .9










Hematocrit .03 1.07 0.999-1.15 .052
AVF, Arteriovenous ﬁstula; AVG, arteriovenous graft; CAD, coronary artery
disease; CI, conﬁdence interval; eGFR, estimated glomerular ﬁltration rate;
HD, hemodialysis; HR, hazard ratio; MI, myocardial infarction; TIA,
transient ischemic attack.
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vitamin D deﬁciency and mortality in this population,
which is a particularly notable ﬁnding given that the
vitamin D-deﬁcient group tended to be younger and had
similar rates of vitamin D supplementation. Our ﬁndings
reinforce the link between vitamin D deﬁciency and
decreased survival and add to a burgeoning body of litera-
ture in various patient populations linking vitamin D deﬁ-
ciency to mortality as well as adverse cardiovascular
outcomes.13,21-30 Observational studies suggest that
vitamin D deﬁciency is associated with an increased risk
of cardiovascular events,31 hypertension, and congestive
heart failure32 and that vitamin D supplementation im-
proves survival.33
However, this study is the ﬁrst that we know of to
show an independent association between vitamin D deﬁ-
ciency and vascular access failure. This ﬁnding is of partic-
ular relevance in this population who is at high risk for
vitamin D deﬁciency and in whom vascular access is so crit-
ical, yet so frequently fails. In addition, we found that
62.5% of patients initiated HD with a catheter. This was
concerning, given that our analysis found that initiating
HD through a catheter was a dramatic independentpredictor of mortality. Vitamin D deﬁciency was not asso-
ciated with primary or secondary patency. The reasons for
loss of primary patency were heterogeneous, including
balloon angioplasty for nonmaturation or outﬂow obstruc-
tion, intrinsic venous disease, or stenosis developing within
a functional graft or ﬁstula. Some of these reasons are
related to vessel wall biology, but others are not. Loss of
primary assisted patency, as we have focused on here,
does reﬂect a loss of functionality that can be most closely
related to vessel wall biology. It is most commonly due to
intimal hyperplasia and thrombosis and is the most clini-
cally relevant end point in this context and, thus, the focus
of this report.
The proposed mechanisms of these associations with
vitamin D deﬁciency and adverse cardiovascular measures
and outcomes include the multiple known immunomodu-
latory and anti-inﬂammatory effects of this steroid hor-
mone. Vitamin D deﬁciency is associated with elevated
circulating markers of inﬂammation and oxidative stress,
including interleukin 6 (IL-6), soluble vascular cell adhe-
sion molecule, malondialdehyde, and myeloperoxidase.34
This is particularly problematic in uremic patients, who
are already in an inﬂammatory state. Histologic analysis
of uremic human vein specimens has shown increased acti-
vation of the innate immune system, with increased expres-
sion of IL-6, transforming growth factor-b and tumor
necrosis factor-a, accompanied by markers of oxidative
damage.35 Correction of vitamin D deﬁciency through
supplementation reduces IL-1b, IL-6, and C-reactive pro-
tein, and raises serum albumin in renally impaired
patients.11,12,36
In addition, ESRD patients have marked endothelial
dysfunction manifested by impaired endothelium-dependent,
ﬂow-mediated vasodilation.17,37-39 This inﬂammatory
state characterized by vitamin D deﬁciency may contribute
to the endothelial dysfunction and development of vascular
disease, and thus, poorer vascular access outcomes.
Our study has several limitations. First, it was a single-
center, observational study, with a relatively small number
of patients. The design of this study did not allow us to
make any inferences about the causal nature of vitamin
D deﬁciency. We can only state the observed associations.
In addition, the small sample size of the study resulted in
very wide CIs. So although we can say that there are as-
sociations between our predictors and outcomes, how
strong these associations are is difﬁcult to say. In addition,
we do not know if this population of patients is different
than the ESRD patients whose vitamin D levels were not
measured.
The active form of vitamin D, plasma 1,25-
dihydroxyvitamin D was not used as a metric in this study.
We were limited by the retrospective nature of this study,
and the active form of vitamin D is rarely measured as part
of clinical routine. Its prohormone, 25-hydroxyvitamin D,
is bound to circulating vitamin D-binding protein, making
it much more stable, with concentrations up to 1000-fold
higher than 1,25-dihydroxyvitamin D, and a signiﬁcantly
longer half-life on the order of weeks as opposed to hours.40
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and labor-intensive methods. For these reasons, serum con-
centrations of 25-hydroxyvitamin D are the most widely
used clinical measure of vitamin D status.
Given the retrospective nature of the study, several fac-
tors were unavailable to us for analysis. For instance, the
difference in serum albumin between the two groups raises
the possibility that the vitamin D level was a surrogate for
overall nutrition in this cohort. However, prealbumin was
not available as a measure to further probe this question
nor were serial measurements of vitamin D, which might
have been informative to see how levels changed over
time, given replacement therapy or not, in relation to our
outcomes of interest.
Finally, time to death or survival analyses were not per-
formed given the lack of routine surveillance and inability
to ascertain exact dates of death in this retrospective study.
Nevertheless, access failure, as deﬁned here, is the most
clinically meaningful access-related event often necessi-
tating the creation of new access and placement of a tem-
porary or permanent central venous catheter.
CONCLUSIONS
This study found that vitamin D deﬁciency is a highly
prevalent condition with serious implications in this patient
population. Given the potential ramiﬁcations of increased
mortality and vascular access failure, further study is war-
ranted to assess if increased scrutiny of vitamin D levels
or aggressive vitamin D repletion will improve survival or
vascular access outcomes in this population.
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